Cargando…

A novel peanut allergy immunotherapy: Plant-based enveloped Ara h 2 Bioparticles activate dendritic cells and polarize T cell responses to Th1

INTRODUCTION: As the only market-authorized allergen immunotherapy (AIT) for peanut allergy is accompanied by a high risk of side effects and mainly induces robust desensitization without sustained efficacy, novel treatment options are required. Peanut-specific plant-derived eBioparticles (eBPs) sur...

Descripción completa

Detalles Bibliográficos
Autores principales: Castenmiller, Charlotte, Nagy, Noémi Anna, Kroon, Pascal Zion, Auger, Lydia, Desgagnés, Réjean, Martel, Caroline, Mirande, Lucie, Morel, Bertrand, Roberge, Joannie, Stordeur, Virginie, Tropper, Guy, Vézina, Louis Philipe, van Ree, Ronald, Gomord, Véronique, de Jong, Esther Christina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: World Allergy Organization 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10679945/
https://www.ncbi.nlm.nih.gov/pubmed/38020282
http://dx.doi.org/10.1016/j.waojou.2023.100839
Descripción
Sumario:INTRODUCTION: As the only market-authorized allergen immunotherapy (AIT) for peanut allergy is accompanied by a high risk of side effects and mainly induces robust desensitization without sustained efficacy, novel treatment options are required. Peanut-specific plant-derived eBioparticles (eBPs) surface expressing Ara h 2 at high density have been shown to be very hypoallergenic. Here, we assessed the dendritic cell (DC)-activating and T cell polarization capacity of these peanut-specific eBPs. METHODS: Route and kinetics of eBP uptake were studied by (imaging) flow cytometry using monocyte-derived DCs incubated with fluorescently-labelled Ara h 2 eBPs or natural Ara h 2 (nAra h 2) in the presence or absence of inhibitors that block pathways involved in macropinocytosis, phagocytosis, and/or receptor-mediated uptake. DC activation was monitored by flow cytometry (maturation marker expression) and ELISA (cytokine production). T cell polarization was assessed by co-culturing DCs exposed to Ara h 2 eBPs or nAra h 2 with naïve CD4(+) T cells, followed by flow cytometry assessment of intracellular IFNγ(+) (Th1) and IL-13(+) (Th2), and CD25(+)CD127(-)Foxp3(+) regulatory T cells (Tregs). The suppressive activity of Tregs was tested using a suppressor assay. RESULTS: Ara h 2 eBPs were taken up by DCs through actin-dependent pathways. They activated DCs demonstrated by an induced expression of CD83 and CD86, and production of TNFα, IL-6, and IL-10. eBP-treated DCs polarized naïve CD4(+) T cells towards Th1 cells, while reducing Th2 cell development. Furthermore, eBP-treated DCs induced reduced the frequency of Foxp3(+) Tregs but did not significantly affect T cell IL-10 production or T cells with suppressive capacity. In contrast, DC activation and Th1 cell polarization were not observed for nAra h 2. CONCLUSION: Ara h 2 eBPs activate DCs that subsequently promote Th1 cell polarization and reduce Th2 cell polarization. These characteristics mark Ara h 2 eBPs as a promising novel candidate for peanut AIT.